Weekly nab-PTX in Combination with Gemcitabine in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum based Chemotherapy
- Conditions
- on-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000017010
- Lead Sponsor
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
- Brief Summary
The overall response rate was 17.9%. The disease control rate was 67.9%. The median progression-free survival was 3.1 months. Adverse events were generally tolerable except grade 3 interstitial pneumonia with in 4 patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 28
Not provided
1)interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)history of drug induced interstitial pneumonia 3)history of severe drug allergy 4)patients previously treated with paclitaxel, gembcitabine, nab-paclitaxel. 5)history of active infection or other serious disease condition 6)history of poorly controlled pleural effusion,pericardial effusion and ascites 7)history of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,heart failure, etc.) 8)uncontrollable diabetes mellitus 9)curative radiotherapy pretreated to the chest. 10)current neuropathy >Grade2 11)history of active double cancer 12)history of active psychological disease 13)history of pregnancy or lactation 14)any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Disease control rate Rate of adverse events